外科理论与实践

外科理论与实践 >

2024 , Vol. 29 >Issue 04: 351 - 357

DOI: https://doi.org/10.16139/j.1007-9610.2024.04.13

论著

华蟾素片联合肝动脉化疗栓塞术治疗原发性肝细胞癌的临床疗效及其影响因素分析

  • 程健珊 ,
  • 张弢 ,
  • 吴珺玮 ,
  • 高惠峰 ,
  • 陈敬贤 ,
  • 孟志强
展开
  • 1.复旦大学附属肿瘤医院中西医结合科，上海 200032
    2.复旦大学上海医学院肿瘤学系，上海 200032
    3.上海交通大学医学院附属瑞金医院 a.普外科；b.肿瘤科；c.中医科，上海 200025
孟志强，E-mail：mengshca@fudan.edu.cn

收稿日期: 2024-04-07

  网络出版日期: 2024-11-15

基金资助

国家临床重点专科(ZDZK1102);国家自然科学基金青年项目(82202839)

收起

Analysis of the efficacy and influence factors for treatment of primary hepatocellular carcinoma by Huachansu tablets combined with transarterial chemoembolization

  • CHENG Chienshan ,
  • ZHANG Tao ,
  • WU Junwei ,
  • GAO Huifeng ,
  • CHEN Jingxian ,
  • MENG Zhiqiang
Expand
  • 1. Department of Integrative Oncology, Shanghai Cancer Center, Fudan University, Shanghai 200032, China
    2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
    3a. Department of General Surgery, b. Department of Oncology，c. Department of Traditional Chinese Medicine, Ruijing Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2024-04-07

  Online published: 2024-11-15

Fold

摘要

目的：评价华蟾素片联合肝动脉化疗栓塞术(TACE)治疗原发性肝细胞癌（HCC）效果及其影响因素。方法：按照纳入和排除标准收集108例HCC病人的临床资料，随机分为试验组和对照组。试验组采用华蟾素片联合TACE治疗，对照组采用单纯TACE治疗。以无进展生存期（PFS）和总生存期（OS）作为评价指标，采用COX回归分析评价两组生存预后及其影响因素。结果：试验组OS 13.5个月，对照组OS 9.2个月；试验组PFS 6.8个月，对照组PFS 5.3个月，组间比较，差异均有统计学意义（P均<0.05）。多因素COX回归分析显示，Child-Pugh分级和肝硬化是HCC病人PFS预后独立的危险因素；Child-Pugh分级是HCC病人OS预后独立的危险因素；ALBI是HCC病人OS预后的保护因素。结论：华蟾素片联合TACE治疗HCC有效延缓肝癌进展，延长病人PFS和OS，其中Child-Pugh分级、肝硬化和ALBI是影响HCC病人预后的重要因素。

关键词： 肝细胞癌; 华蟾素; 肝动脉化疗栓塞术; 影响因素

本文引用格式

程健珊 , 张弢 , 吴珺玮 , 高惠峰 , 陈敬贤 , 孟志强 . 华蟾素片联合肝动脉化疗栓塞术治疗原发性肝细胞癌的临床疗效及其影响因素分析[J]. 外科理论与实践, 2024 , 29(04) : 351 -357 . DOI: 10.16139/j.1007-9610.2024.04.13

Abstract

Objective To evaluate the efficacy of Huachansu tablets combined with transarterial chemoembolization (TACE) for treatment of primary hepatocellular carcinoma (HCC) and prognostic influence factors. Methods One hundred and eight patients with HCC were recruited according to the inclusion and exclusion criteria. Patients were randomly divided into treatment group and control group. The treatment group was treated with Huachansu tablets combined with TACE, and the control group was treated with TACE alone, with overall survival time (OS) and progression-free survival time (PFS) as the evaluation indexes. The COX regression analysis was used to evaluate the survival and prognostic effects and their influence factors in both groups. Results A total of 108 HCC patients were enrolled. The OS was 13.5 months in treatment group and 9.2 months in control group; the PFS was 6.8 months in treatment group and 5.3 months in control group, and the differences were significant statistically (all P<0.05). Multivariate COX regression analysis showed that Child-Pugh grade and cirrhosis were the independent risk factors for PFS in HCC patients. Child-Pugh grade were the independent risk factors for OS in HCC patients. ALBI is a protective factor for OS in HCC patients. Conclusions The treatment of HCC by Huachansu tablets combined with TACE can delay the progression of HCC and prolong PFS and OS of the patients with HCC. Child-Pugh grade, cirrhosis status, and ALBI were important factors affecting the prognosis of the patients with HCC.

Key words： Hepatocellular carcinoma(HCC); Huachansu tablet; Transarterial chemoembolization(TACE); Influencing factor

参考文献

[1 ] LI J, ZHANG L, TAO Y, et al. Combination of transca-theter arterial chemoembolization and anti-PD-L1 liposomes therapy suppressed hepatocellular carcinoma progression in mice[J]. Eur J Pharm Sci, 2023,189:106549.
[2] ZHU H, WANG S Y, ZHU J H, et al. Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment[J]. Phytomedicine, 2021,91:153700.
[3] LIU D, SONG T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China[J]. Biosci Trends, 2021, 15(3):142-147.
[4] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
[5] PAN Y X, SUN X Q, HU Z L, et al. Prognostic values of alpha-fetoprotein and des-gamma-carboxyprothrombin in hepatocellular carcinoma in China: an analysis of 4792 patients[J]. J Hepatocell Carcinoma, 2021,8:657-670.
[6] HAO M Z, LIN H L, CHEN Q Z, et al. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma[J]. J Dig Dis, 2017, 18(1):31-39.
[7] 陈良, 刘艳芳, 孙勤学, 等. 射频消融联合肝动脉化疗栓塞治疗直径3cm以上原发性肝癌的疗效和影响因素分析[J]. 现代实用医学, 2019, 31(5):590-592.
  CHEN L, LIU Y F, SUN Q X, et al. Efficacy and influencing factors analysis of radiofrequency ablation combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer with a diameter greater than 3cm[J]. Mod Pract Med, 2019, 31(5):590-592.
[8] LI W, PEI S, ZHANG X, et al. Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate beta-catenin in vitro and in vivo[J]. Eur J Pharmacol, 2022,922:174886.
[9] CHENG L, CHEN Y Z, PENG Y, et al. Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells[J]. Tumour Biol, 2015, 36(8):5763-5771.
[10] 孙志刚, 李佳, 焦勤书, 等. 动脉置管灌注华蟾素注射液联合索拉非尼治疗经动脉化疗栓塞术后原发性肝癌患者近期疗效观察[J]. 中华中医药学刊, 2022, 40(5):223-226.
  SUN Z G, LI J, JIAO Q S, et al. Observation of short-term curative effect of intra-arterial infusion of cinobufacini injection combined with sorafenib in treatment of patients with primary liver cancer after TACE[J]. Chin Arch Tradit Chin Med, 2022, 40(5):223-226.
[11] 周昕, 杨金坤, 朱玲琦, 等. 华蟾素注射液应用于介入治疗肝癌的Meta分析[J]. 中国新药与临床杂志, 2009, 28(9):671-674.
  ZHOU X, YANG J K, ZHU L Q, et al. Meta analysis on cinobufacini injection in hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Chin J New Drugs Clin Rem, 2009, 28(9):671-674.
[12] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8):1419-1431.
  National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8):1419-1431.
[13] WEILER S, LUTZ T, BISSINGER M, et al. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells[J]. Cancer Lett, 2020,473:164-175.
[14] 齐秀恒, 武振明, 刘琪, 等. 恩度肝动脉灌注联合介入化疗栓塞治疗中晚期肝癌的临床观察[J]. 中国肿瘤临床, 2008, 35(1):5-7.
  QI X H, WU Z M, LIU Q, et al. Intrahepatic arterial infusion of endostar combined with transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma[J]. Chin Clin Oncol, 2008, 35(1):5-7.
[15] 田国标, 朱江, 陈晓波, 等. 肝动脉介入化疗栓塞术治疗肝癌的疗效[J]. 血管与腔内血管外科杂志, 2023, 9(5):553-556.
  TIAN G B, ZHU J, CHEN X B, et al. Efficacy of transarterial chemoembolization for liver cancer[J]. J Vasc Endovascular Surg, 2023, 9(5):553-556.
[16] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤综合治疗电子杂志, 2022, 8(2):16-53.
  National Health Commission of the People's Republic of China. Guidelines for the diagnosis and treatment of primary liver cancer(2022)[J]. J Multidiscip Cancer Manage, 2022, 22(8):16-53.
[17] 周旭林, 满沐苒, 王璐璐, 等. 肝动脉化疗栓塞联合放疗治疗中晚期肝癌疗效与安全性的荟萃分析[J]. 介入放射学杂志, 2019, 28(5):428-435.
  ZHOU X L, MAN M R, WANG L L, et al. TACE combined with radiotherapy for the treatment of mid-stage and advanced liver cancers:a meta-analysis of its clinical efficacy and safety[J]. J Intervent Radiol, 2019, 28(5):428-435.
[18] 刘旭, 邵瑞, 田晓轩, 等. 华蟾素抗肿瘤研究进展[J]. 中国实验方剂学杂志, 2019, 25(5):229-234.
  LIU X, SHAO R, TIAN X X, et al. Research progress on anti-tumor of cinobufacini[J]. Chin J Exp Tradit Med Formulae, 2019, 25(5):229-234.
[19] 熊飞, 施嫣嫣, 沈久成, 等. 华蟾素对肺癌NCI-A549移植瘤裸鼠的抑制作用及机制研究[J]. 中国临床药理学与治疗学, 2018, 23(10):1103-1108.
  XIONG F, SHI Y Y, SHEN J C, et al. Inhibitory effect and mechanism of cinobufotalin on lung cancer NCIA549 xenograft in nude mice[J]. Chin J Clin Pharmacol Ther, 2018, 23(10):1103-1108.
[20] 任思思, 范妤, 郭东艳, 等. 华蟾素注射液联合西医疗法治疗肝癌有效性与安全性的系统评价Meta分析[J]. 海南医学院学报, 2023, 29(6):452-462.
  REN S S, FAN Y, GUO D Y, et al. Systematic evaluation and meta-analysis of the efficacy and safety of cinobufagin injection combined with western medicine in the treatment of liver cancer[J]. J Hainan Med Univ, 2023, 29(6):452-462.
[21] 杨建波, 刘鹏, 张文兴, 等. 华蟾素通过IGF-1R信号通路对肝癌细胞增殖、迁移及侵袭的影响[J]. 中医学报, 2021, 36(12):2636-2641.
  YANG J B, LIU P, ZHANG W X, et al. Effect of cinobufavirin on proliferation, migration and invasion of hepatoma cells through IGF-1R signaling pathway[J]. Chin J Chin Med, 2021, 36(12):2636-2641.
[22] 倪腾洋, 李丹, 王海波, 等. 华蟾素通过调控基质金属蛋白酶抑制人胃腺癌细胞MGC-803侵袭与迁移[J]. 中国实验方剂学杂志, 2018, 24(19):106-111.
  NI T Y, LI D, WANG H B, et al. Effect of cinobufacini on invasion and migration of human gastric cancer MGC-803 cells by regulating matrix metalloproteinases[J]. Chin J Exp Tradit Med Formulae, 2018, 24(19):106-111.
[23] 孟志强, 沈晔华, 杨培英, 等. 华蟾素治疗肝癌、肺癌、胰腺癌的Ⅰ期临床研究:初步报道[J]. 中国癌症杂志, 2007, 17(5):376-379.
  MENG Z Q, SHEN Y H, YANG P Y, et al. PhaseⅠstudy of huachansu in hepatocellular carcinoma,non-small cell lung cancer,and pancreatic cancer:a preliminary report[J]. China Oncol, 2007(5):376-379.
[24] NUMAZAWA S, INOUE N, NAKURA H, et al. A cardiotonic steroid bufalin-induced differentiation of THP-1 cells. Involvement of Na+, K(+)-ATPase inhibition in the early changes in proto-oncogene expression[J]. Biochem Pharmacol, 1996, 52(2):321-329.
[25] JYOTI S, TANDON S. Disruption of mitochondrial membrane potential coupled with alterations in cardiac biomarker expression as early cardiotoxic signatures in human ES cell-derived cardiac cells[J]. Hum Exp Toxicol, 2019, 38(9):1111-1124.
[26] LI H, WANG P, GAO Y, et al. Na+/K+-ATPase alpha3 mediates sensitivity of hepatocellular carcinoma cells to bufalin[J]. Oncol Rep, 2011, 25(3):825-830.
[27] 赵首捷, 杨振宇, 雷世雄, 等. Child-Pugh评分和ALBI分级对BCLC-B期肝癌生存预后预测价值比较[J]. 中华肝脏外科手术学电子杂志, 2021, 10(1):38-42.
  ZHAO S J, YANG Z Y, LEI S X, et al. Comparison of prognostic value between Child-Pugh score and albumin-bilirubin grading for patients with BCLC-B stage hepatocellular carcinoma[J]. Chin J Hepat Surg(Electronic Edition), 2021, 10(1):38-42.
[28] 赵春华, 耿烨芳. 肝脏储备功能评估方法的研究现状[J]. 诊断学理论与实践, 2015, 14(4):371-374.
  ZHAO C H, GENG Y F. Research status of assessment methods for liver reserve function[J]. J Diagn Concepts Pract, 2015, 14(4):371-374.
[29] 李斌, 杨建峰, 吕单玲, 等. 肝硬化CT分级对肝癌介入治疗后肝储备功能及预后的评估价值[J]. 浙江实用医学, 2019(4):271-272,281.
  LI B, YANG J F, LV D L, et al. The assessment value of CT grading for liver cirrhosis in evaluating hepatic reserve function and prognosis after interventional treatment for liver cancer[J]. Zhejiang Pract Med, 2019(4):271-272,281.
[30] LUO P, WU S, YU Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020, 26(2):599-603.
Options
文章导航

/

〈 〉